In a recent report, the authors identified that acacetin (10–20 mg/kg) could significantly reduce hypertension-induced ventricular fibrosis in SHR and inhibit angiotensin II (Ang II)-stimulated proliferation, migration, and myofibroblast transformation in human cardiac fibroblasts, implying that acacetin could serve as a promising therapeutic agent for MF (Li et al., 2023). This evidence concerns the gene AGT and hypertensive disorder.